Aosaikang: Innovative drug ASKB589 will announce clinical research data at the 2025 ESMO Annual Meeting
I'm PortAI, I can summarize articles.
ASK PHARM announced that its subsidiary ASKGENE LIMITED will present clinical research data for the biopharmaceutical ASKB589 at the 2025 ESMO Annual Meeting. The drug, in combination with CAPOX and PD-1 inhibitors, has shown deep and lasting tumor remission and disease control in first-line treatment of advanced gastric cancer, with clear survival benefits. These positive clinical data will enhance the market competitiveness of the company's products
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments